AF
MDGL icon

Amalgamated Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Amalgamated Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$188K Buy
+1,919
New +$162K ﹤0.01% 1923

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Amalgamated Financial's MDGL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2022: 1,919 shares worth $188K. The stake represents ﹤0.01% of the portfolio and ranks #1923 among its holdings.

140 funds tracked by Wall St. Rank hold MDGL as of Q1 2022.

  • Amalgamated Financial held 1,919 shares of Madrigal Pharmaceuticals worth $188K as of Q1 2022.
  • Madrigal Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1923 holding.
  • 140 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.